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p–p InteractionsAbstract Preparations of 2-(4-ﬂuorobenzyl)-6-phenylimidazo[2,1-b][1,3,4]thiadiazole (3a) and its
chlorophenyl derivative (3b) are described. Preliminary analysis was done spectroscopically by
means of 1H NMR, 13C NMR spectra, mass spectra and elemental analyses. Further the structures
were conﬁrmed by X-ray crystal structure analyses. The compound (3a) has crystallized in a triclinic
P-1 space group with three independent molecules in the asymmetric unit, while the compound (3b)
belongs to P21/c space group with one molecule in the asymmetric unit. The molecule (3b) differs
from molecule (3a) by the presence of chlorine substituent. Additionally, the imidazo-thiadiazole
entity is as usual planar. Intramolecular C–H  N hydrogen bonding between the imidazole and
the phenyl ring of the molecule can be observed in (3a) & (3b). The molecules of (3a) are linked into
two dimensional supramolecular hexagonal hydrogen bonded network sustained by C–H  F inter-
action, while those of (3b) are linked by bifurcated C–H  N interactions. Further, the molecular
packing of both the compounds is stabilized by p–p stacking interactions between the benzene
and imidazo-thiadiazole ring systems.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University.
Open access under CC BY-NC-ND license.1. Introduction
A large number of imidazo[2,1-b][1,3,4]thiadiazole derivatives
have been reported to possess diverse medicinal properties
which can be classiﬁed as anthelmintic, antimicrobial, anti-
inﬂammatory, antipyretic, analgesic and they also have other
characteristics of therapeutic signiﬁcance (Khazi et al., 2004;
Palagiano et al., 1995). 1,3,4-Thiadiazoles are known for their
promising biological and pharmacological activities, possibly
due to the presence of pharmacophoric isothioamide
(S–C‚N–) unit (Banu et al., 2010) in the thiadiazole nucleus.
372 A. Banu et al.Secondly, the thiadiazole ring is bioisosteric with the
thiazole moiety of the novel broad spectrum anthelmintic
tetramisole (Kumar et al., 2010). Some thiadiazole derivatives
are reported to possess anti-cancer properties (Sanff et al.,
2004; Rzeski et al., 2007). They appeared to be the
most feasible route to fused imidazo[2,1-b][1,3,4] thiadiazole
rings of interest in potential applications (Amery et al., 1984).
Apart from this, ﬂuorinated compounds in general and
ﬂuorinated heterocyclic compounds in particular, are the focus
of much interest in modern medicinal chemistry. In other clas-
ses of antitumour compounds, e.g. the anthracycline antibiot-
ics (Miller and Stoodley, 2013), the substitution of a hydrogen
atom for a ﬂuorine atom in the tetracyclic ring system was
found to possess better antitumour properties (Animati
et al., 1996).
Moreover the presence of a ﬂuoro substituent in themolecule
enhances its biological activity. Accumulation of ﬂuorine
(Strunecka et al., 2004) on carbon leads to increased oxidative
and thermal stability. Further it leads to increased lipid
solubility which enhances the rate of absorption and transport
of the drug in vivo. These ﬁndings prompted the synthesis of
the title compounds. A single crystal X-ray diffraction analysis
was carried out to establish the crystal structure and to
understand the self-aggregation in terms of possible
intermolecular interactions.
In the course of our structural studies of the family of
imidazo-thiadiazole derivatives, we report here the structures
of two such compounds, namely 2-(4-ﬂuorobenzyl)-
6-phenylimidazo[2,1-b][1,3,4]thiadiazole and its 6-(4-chloro-
phenyl) derivative. The syntheses of these compounds were
followed by measurement of their analytical data and subse-
quent spectroscopic analyses using 1H NMR, 13C NMR spec-
tra, mass spectra and elemental analyses techniques to conﬁrm
the presence of the supposed ring systems, presence of ﬂuoro
and chloro substituents as well as the signals for the existence
of various protons. A single crystal X-ray diffraction analysis
was carried out for the two compounds in order to establish
the crystal as well as molecular structures and to understand
the self-aggregation in terms of possible intermolecular inter-N
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to the  carbonyl carbonactions. The analyses revealed structural features such as the
orthogonal orientation of the ﬂuorobenzyl group to the rest
of the molecule, presence of various intermolecular interac-
tions involving the hexagonal hydrogen bond network and
p–p interactions.2. Experimental
2.1. Materials
All reagents were obtained from commercial sources. Solvents
were dried and puriﬁed with known conventional methods.
2.2. Analytical methods
The melting points were determined in open capillaries and are
uncorrected. The IR spectra were recorded as KBr discs using a
Nicolet FT-IR 410 spectrophotometer. 1H NMR spectra were
recorded on a Varian RXZ-300 MHz spectrometer using TMS
as internal reference compound. C,H andNwere estimated on a
Heraus CHN rapid analyzer at KarnatakUniversity, Dharwad,
India. The title compounds were prepared following the proce-
dure given below and as shown in Scheme 1.
2.3. Procedure for the preparation of 2-(4-ﬂuorobenzyl)-
6-phenylimidazo[2,1-b][1,3,4]thiadiazole (3a) and its chloro-
phenyl derivative (3b)
A mixture of 5-(4-ﬂuorobenzyl)-1,3,4-thiadiazol-2-amine (1)
(Khazi et al., 2004) (2.69 g, 0.01 mol) and phenacyl bromide
(2a) (0.01 mol) was reﬂuxed in dry ethanol for 12 h. The
excess of solvent was distilled off and the solid
hydrobromide salt that separated was collected by ﬁltration,
suspended in water and neutralized by aqueous sodium
carbonate solution to get the free base (3a). It was ﬁltered,
washed with water, dried and recrystallized from ethyl
acetate to afford white needles with good yield of 75% (2.98 g).
The same procedure was followed to obtain (3b) wherein (1)
was treated with p-chloro phenacyl bromide (2b). The crystals
of (3b) were obtained by recrystallization using ethanol sol-
vent. Yield 70% (3.08 g).
2.3.1. Mechanism2.3.2. 2-(4-Fluorobenzyl)-6-phenylimidazo[2,1-b][1,3,4]-
thiadiazole (3a)
Brown crystalline Solid (ethanol + dioxan), yield 75%, m.p.
168–170 C; IR (KBr) m cm1: 3124 (‚CH), 2923, 2853
(–CH), 1602, 1507 (C‚N); 1H NMR (300 MHz, CDCl3) d:
Br
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Scheme 1 Syntheses of compounds 3a and 3b.
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J= 7.2 Hz, 2H, Ar–H), 7.98 (s, 1H, C5–H, imidazole).
13C
NMR (75 MHz, CDCl3) d: 13C NMR (75 MHz, CDCl3) d:
37.8 (–CH2–), 109.6–164.4 (C of imidazo-thiadiazole and 2
Ars), MS (m/z): 309. Anal. calcd. for C17H12FN3S: C, 66.01;
H, 3.88; N, 13.59. Found: C, 66.10; H, 3.82; N, 13.62%.
2.3.3. 6-(4-Chlorophenyl)-2-(4-ﬂuorobenzyl)imidazo[2,1-
b][1,3,4]thiadiazole (3b)
Shining white needles (ethanol + dioxan), yield 70%, m.p.
173–175 C; IR (KBr) m cm1: 3016, 2859, 2817, 1603, 1504;
1H NMR (300 MHz, CDCl3) d: 4.29 (s, 2H, CH2), 7.05–7.42
(m, 6H, Ar–H), 7.64 (d, J= 7.3 Hz, 2H, Ar–H), 7.96 (s, 1H,
C5–H, imidazole).
13C NMR (75 MHz, CDCl3) d: 13C NMR
(75 MHz, CDCl3) d: 37.8 (–CH2–), 109.6–164.4 (C of imi-
dazo-thiadiazole and 2 Ars), MS (m/z): 343. Anal. calcd. for
C17H11FClN3S: C, 59.47; H, 3.20; N, 20.58. Found: C,
59.28; H, 3.24; N, 20.51%.
3. X-ray diffraction analysis
The X-ray diffraction data, for both compound (3a) and
compound (3b) were collected on a Bruker Smart CCD Area
Detector System at I.I.Sc., Bangalore, using MoKa
(0.71073 A˚) radiation for the crystal. The data were reduced
using SAINTPLUS (Bruker, 1998). The structure was solved
by direct methods using SHELXS97 (Sheldrick, 2008) and
difference Fourier synthesis using SHELXL97 (Sheldrick,
2008). The positions and anisotropic displacement
parameters of all non-hydrogen atoms were included in the
full-matrix least-square reﬁnement using SHELXL97
(Sheldrick, 2008) and the procedures were carried out for a
few cycles until convergence was reached. The H atoms were
placed at calculated positions in the riding model
approximation (C–H 0.93 A˚); their temperature factors were
set to 1.2 times those of the equivalent isotropic temperature
factors of the parent atoms. All other non-H atoms were
reﬁned anisotropically. Molecular diagrams were generated
using ORTEP (Farrugia, 1997). The mean plane calculation
was done using the program PARST (Nardelli, 2010).
3.1. Compound (3a)
Intensity data were collected up to a maximum of 27.00 for
the compound in the x–a scan mode. A total of 13113 reﬂec-
tions were collected, resulting in 9234 independent reﬂections
of which the number of reﬂections satisfying I>2 r(I) criteria
were 7000. These were treated as observed. The R factor forobserved data ﬁnally converged to R= 0.0857 with wR2 =
0.2363 in the compound. The maximum and minimum values
of residual electron density were 2.870 and 0.687 e A˚3.
3.2. Compound (3b)
Intensity data were collected up to a maximum of 27.00 for
the compound in the x–a scan mode. A total of 8553 reﬂec-
tions were collected, resulting in 3238 independent reﬂections
of which the number of reﬂections satisfying I>2 r(I) criteria
were 2307. These were treated as observed. The R factor for
observed data ﬁnally converged to R= 0.0540 with wR2 =
0.1394 in the compound. The maximum and minimum values
of residual electron density were 0.484 and 0.419 e A˚3.
4. Results and discussion
4.1. Chemistry
The reaction of 2-amino-5-(4-ﬂuoro-benzyl)-1,3,4-thiadiazole
(1) (Giri et al., 1964) and phenacyl bromide (2) in boiling
ethanol afforded the 2-(4-ﬂuoro-benzyl)-6-phenyl-
imidazo[2,1-b][1,3,4]thiadiazole (3) as hydrobromide salt,
which was neutralized by sodium carbonate solution to get
the free base. It is well established that this reaction proceeds
via the intermediate iminothiadiazole which under reﬂux
temperature spontaneously undergoes dehydrocyclisation to
form the desired fused heterocycle (Gadad et al., 2000).
Various a-haloaryl ketones were prepared by the
bromination of the corresponding ketones.
Structures of imidazothiadiazole derivatives (3a–b) were
established by the absence of tN–H band in the IR spectra
and appearance of imidazole proton (C5–H) around d 8 in
the 1H NMR spectra. The 13C NMR and mass spectra of these
compounds further conﬁrmed the assigned structures. A num-
ber of compounds containing 2-benzyl-6-phenyl-imidazo[2,1-
b][1,3,4] thiadiazole as the basic structural unit with various
substituents have been synthesized earlier and spectroscopi-
cally analyzed and reported (Badiger et al., 2009; Gupta
et al., 1993). Good quality single crystals for compounds (3a)
and (3b) were prepared by slow evaporation method using
ethyl acetate and ethanol solvents. Crystals grown are stable
for a long-time in normal conditions of temperature and
humidity. The chemical formula was determined when resolv-
ing the crystal structure by X-ray diffraction. In the present
work, we report the synthesis and spectroscopic analysis of
the two title compounds with more emphasis laid on weak
interactions.
Figure 1 ORTEP diagram of the three independent molecules present in the asymmetric unit of compound (3a), showing 50%
probability displacement ellipsoids and the atom-numbering scheme. Dotted line indicates CAHÆÆÆN interaction.
Figure 2 ORTEP diagram of compound (3b), showing 50% probability displacement ellipsoids and the atom-numbering scheme.
Table 1 Crystal data and structure reﬁnement for (3a).
Empirical formula C17H12FN3S
Formula weight 309.36
Temperature 296(2) K
Wavelength 0.71073 A˚
Crystal system, space group Triclinic, P1
Unit cell dimensions
a= 5.582 A˚ a= 117.06
b= 20.888 A˚ b= 94.81
c= 21.405 A˚ c= 94.89
Volume 2193.0 A˚3
Z 6
Calculated density 1.405 mg/m3
Absorption coeﬃcient 0.231 mm1
F(0 0 0) 960
Crystal size 0.18 · 0.16 · 0.16 mm
Theta range for data collection 1.91–27.00 
Limiting indices 7  h  7, 19  k  26,
27  l  23
Reﬂections collected/unique 13,113/9234 [R(int) = 0.0413]
Completeness to theta 27.00, 96.6%
Absorption correction Multi scan
Max. and min. transmission 0.9639 and 0.9596
Reﬁnement method Full-matrix least-squares on F2
Data/restraints/parameters 9234/0/595
Goodness-of-ﬁt on F2 1.144
Final R indices [I>2 r(I)] R1 = 0.0857, wR2 = 0.2363
R indices (all data) R1 = 0.1101, wR2 = 0.2800
Largest diﬀ. peak and hole 2.870 and 0.687 e A˚3
Table 2 Crystal data and structure reﬁnement for (3b).
Empirical formula C17H11ClFN3S
Formula weight 343.80
Temperature 296(2) K
Wavelength 0.71073 A˚
Crystal system, space group Monoclinic, P21/n
Unit cell dimensions
a= 10.255(4) A˚
b= 5.618(3) A˚
c= 26.044(1) A˚
b= 91.438(8)
Volume 1499.9(11) A˚3
z 4
Calculated density 1.523 mg/m3
Absorption coeﬃcient 0.406 mm1
F(000) 704
Crystal size 0.18 · 0.16 · 0.16 mm
Theta range for data collection 2.15–27.00
Limiting indices 12  h  13, 7  k  7,
33  l  19
Reﬂections collected/unique 8553/3238 [R(int) = 0.0549]
Completeness to theta 27.00, 99.3%
Max. and min. transmission 0.9379 and 0.9305
Reﬁnement method Full-matrix least-squares on F2
Data/restraints/parameters 3238/0/212
Goodness-of-ﬁt on F2 1.080
Final R indices [I>2 r(I)] R1 = 0.0540, wR2 = 0.1394
R indices (all data) R1 = 0.0805, wR2 = 0.1705
Largest diﬀ. peak and hole 0.484 and 0.419 e A˚3
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Table 3 Selected bond lengths [A˚] and angles [] for compound (3a).
C1–C12 1.509(6)/1.516(6)/1.503(6) N3–C3–S1 138.0(3)/138.2(3)/138.6(3)
C1–C2 1.502(6)/1.515(6)/1.513(6) N2–C3–S1 109.1(3)/108.9(3)/108.6(3)
C2–N1 1.300(5)/1.297(5)/1.286(5) N2–C4–C6 104.7(4)/104.9(4)/104.5(4)
C2–S1 1.750(4)/1.743(4)/1.751(4) C11–C5–C7 118.7(4)/118.8(4)/117.9(4)
C3–N3 1.314(5)/1.317(5)/1.312(5) C11–C5–C6 120.8(4)/121.1(4)/120.9(4)
C3–N2 1.362(5)/1.365(5)/1.360(5) C7–C5–C6 120.5(4)/120.1(4)/121.2(4)
C3–S1 1.729(4)/1.734(4)/1.732(4) C4–C6–N3 111.7(4)/112.0(4)/111.6(4)
C4–N2 1.362(5)/1.379(5)/1.367(5) C4–C6–C5 127.9(4)/127.4(4)/128.2(4)
C4–C6 1.365(5)/1.370(5)/1.372(6) N3–C6–C5 120.4(4)/120.6(4)/120.2(4)
C5–C11 1.394(5)/1.394(5)/1.390(6) C8–C7–C5 120.7(4)/119.8(4)/122.0(4)
C5–C7 1.395(5)/1.393(6)/1.399(5) C7–C8–C9 120.6(4)/121.2(5)/119.5(4)
C5–C6 1.481(6)/1.477(5)/1.466(5) C8–C9–C10 118.8(4)/119.6(4)/119.2(4)
C6–N3 1.393(5)/1.391(5)/1.393(5) C11–C10–C9 120.7(4)/119.8(4)/120.4(4)
C7–C8 1.383(6)/1.395(6)/1.383(6) C10–C11–C5 120.6(4)/120.7(4)/121.0(4)
C8–C9 1.392(6)/1.368(6)/1.392(6) C17–C12–C1 118.6(5)/119.6(5)/118.2(5)
C9–C10 1.394(6)/1.385(6)/1.392(6) C17–C12–C1 120.9(5)/120.5(4)/121.4(4)
C10–C11 1.387(6)/1.397(6)/1.394(6) C13–C12–C1 120.3(4)/119.7(5)/120.4(5)
C12–C13 1.395(7)/1.389(6)/1.393(6) C14–C13–C12 121.3(5)/121.1(5)/121.9(5)
C12–C17 1.370(6)/1.380(6)/1.394(7) C13–C14–C15 117.9(5)/116.8(5)/117.7(5)
C13–C14 1.377(7)/1.397(7)/1.373(7) F1–C15–C16 119.1(5)/117.8(5)/118.2(5)
C14–C15 1.380(7)/1.374(6)/1.379(7) F1–C15–C14 118.2(5)/118.4(5)/118.9(5)
C15–C16 1.375(7)/1.374(6)/1.374(7) C16–C15–C14 122.7(5)/123.8(5)/122.9(5)
C16–C17 1.387(7)/1.386(7)/1.382(7) C15–C16–C17 117.7(5)/118.4(5)/118.5(5)
C15–F1 1.364(5)/1.369(5)/1.356(6) C12–C17–C16 121.6(5)/120.2(5)/120.8(5)
N1–N2 1.375(5)/1.363(4)/1.374(5) C2–N1–N2 108.3(4)/108.4(4)/108.0(4)
C4–N2–C3 107.6(4)/106.7(4)/107.7(4)
C12–C1–C2 111.4(4)/110.5(4)/111.9(4) C4–N2–N1 134.5(4)/135.5(4)/133.9(4)
N1–C2–C1 122.9(4)/122.3(4)/123.1(4) C3–N2–N1 117.8(4)/117.4(4)/117.7(4)
N1–C2–S1 116.6(3)/120.4(4)/117.2(3) C3–N3–C6 103.0(3)/103.5(4)/103.5(4)
C1–C2–S1 120.5(3)/117.3(3)/119.8(3) C3–S1–C2 88.1(2)/87.7(2)/87.8(2)
N3–C3–N2 112.9(4)/112.8(4)/112.8(4)
* The values given after 1st/corresponds to molecule B whereas 2nd/to molecule C.
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The details of crystal data and reﬁnements are given in Tables 1
and 2 for the compounds (3a) and (3b) respectively. The
selected bond distances and angles for compound (3a) and
(3b) are given in Tables 3 and 4, respectively. Tables 5 and 6
give their respective hydrogen bond interactions. The ORTEP
diagrams of the molecules 3a and 3b are shown in Figs. 1 and
2, respectively. Figs. 3–5 show the hydrogen bond interactions
in crystal structure of (3a) and (3b), respectively.
The compound (3a) has three independent molecules in the
asymmetric unit. The central imidazo-thiadiazole unit is linked
to the ﬂuorobenzyl group at one end and the phenyl ring at the
other. The dihedral angles between ﬂuorobenzyl and imidazo-
thiadaizole rings is orthogonally inclined at an angle 88.25(6)/
81.43(2)/82.79(8) (the three values corresponds to the three
independent molecules) and angles between imidazo-
thiadiazole and phenyl ring 8.65(3)/10.21(6)/10.21(6) repre-
sent the co-planarity of the molecule.
The average value of the bond distances is 1.388(6) A˚ while
the exocyclic bond angles [120.6(8)] in the phenyl rings of the
molecule have normal values which agree quite well with the
values reported in the literature for some analogous structures
(Toda et al., 1998; Li et al., 1992). The survey of the structure
at a molecular level reveals the usual geometrical parameters
for the S–C bond of 1.731(5) A˚. The N–C and N–N bonds of
the three independent molecules A, B and C are 1.360(6) A˚/
1.354 A˚/1.358 A˚ and 1.380 A˚/1.352(2) A˚/1.375 A˚, respectivelywhich are shorter than typical bond lengths due to the p-electron
delocalization. The C‚N bond length of 1.310(7) A˚ conﬁrms it
as a double bond. The orientation of ﬂuorobenzyl group is
characterized by torsion angles C(17A)-C(12A)-C(1A)-C(2A)
of 85.1(6), C(17B)-C(12B)-C(1B)-C(2B) of 83.7(5) and
C(13C)-C(12C)-C(1C)-C(2C) of 86.0(6) in molecules A, B
and C, respectively.
The most interesting feature of this compound is the ana-
lyzes of the crystal packing indicating intra and intermolecular
interactions. All the three molecules in the asymmetric unit are
primarily stabilized by two strong intramolecular C–H  N
hydrogen bonds in the crystal structure leading to the forma-
tion of a pseudo-ﬁve-membered hydrogen bonded pattern with
graph set S(5) which locks the molecular conformation while
eliminating conformational ﬂexibility.
The crystal structure of compound (3a) is further stabilized
by intermolecular C–H  N and C–H  F hydrogen bonds.
There are twoC–H  N interactions, the former generates bifur-
cated bonds from two donor atoms, C4 and C14 to the same
acceptor, N3 linking the dimers into a tape like pattern while
the latter leads to the formation of centrosymmetric head to
head dimers corresponding to graph set notation R22(14)
(Bernstein et al., 1995) along ‘a’ axis (Fig. 3). These C–H  N
hydrogen bonds have been extensively used in crystal
engineering (Desiraju, 1991, 1995, 1996, 1997a,b; Steiner, 1996).
The intermolecular C–H  F interaction of the molecule
leads to the two dimensional supramolecular porous network
of hexagonal hydrogen bond pattern in the crystal structure
Table 5 Non-bonded interactions and possible hydrogen
bonds (A˚, ) for compound (3a) (D-donor; A-acceptor; H-
hydrogen).
D–H  A D–H H  A D  A D–H  A
C16a–H16a  N3b 0.930(5) 2.537(4) 3.434(7) 162
C14b-H14b  N3c 0.930(5) 2.641(4) 3.536(6) 162
C4a-H4a  .N3ai 0.930(6) 2.917(4) 3.527(6) 124
C14C–H14c  N3aii 0.930(6) 2.663(4) 3.536(8) 156
C17C–H17c  F1bi 0.930(6) 2.570(4) 3.344(8) 141
C13a–H13a  F1ciii 0.930(5) 2.523(3) 3.351(6) 148
C17b–H17b  F1aiv 0.930(6) 2.445(4) 3.284(7) 150
C7b–H7b  N1bv 0.930(4) 2.740(3) 3.607(5) 155
Symmetry code: (0) x, y, z; (i) x1, +y, +z; (ii) x, y, z+1; (iii)
x1, y, z+1; (iv) x+1, +y, +z; (v) x+2, y+1, z+1.
Table 6 Non-bonded interactions and possible hydrogen
bonds (A˚, ) for compound (3b) (D-donor; A-acceptor; H-
hydrogen).
D–H  A D–H H  A D  A D–H  A
C11–H11  N3 0.930(3) 2.567(3) 2.894(4) 101
C1–H1b  N3i 0.970(3) 2.571(2) 3.431(4) 148
C4–H4  N3ii 0.977(3) 2.658(4) 3.501(4) 147
Symmetry code: (0) x, y, z (i) x+1/2, +y1/2, z+1/2; (ii) x,
+y1, +z.
Table 4 Selected bond lengths [A˚] and angles [] for
compound (3b).
C(1)–C(2) 1.497(4) N(2)–C(3)–S(1) 109.0(2)
C(1)–C(12) 1.499(4) N(2)–C(4)–C(6) 104.6(3)
C(2)–N(1) 1.289(4) C(11)–C(5)–C(7) 117.8(3)
C(2)–S(1) 1.750(3) C(11)–C(5)–C(6) 120.7(3)
C(3)–N(3) 1.330(4) C(7)–C(5)–C(6) 121.5(3)
C(3)–N(2) 1.357(4) C(4)–C(6)–N(3) 111.4(3)
C(3)–S(1) 1.729(3) C(4)–C(6)–C(5) 127.6(3)
C(4)–N(2) 1.371(4) N(3)–C(6)–C(5) 121.0(3)
C(4)–C(6) 1.375(4) C(8)–C(7)–C(5) 121.7(3)
C(5)–C(11) 1.392(4) C(7)–C(8)–C(9) 118.9(3)
C(5)–C(7) 1.404(4) C(10)–C(9)–C(8) 121.3(3)
C(5)–C(6) 1.462(4) C(10)–C(9)–Cl(1) 119.5(3)
C(6)–N(3) 1.395(4) C(8)–C(9)–Cl(1) 119.2(3)
C(7)–C(8) 1.378(4) C(9)–C(10)–C(11) 119.3(3)
C(8)–C(9) 1.386(5) C(5)–C(11)–C(10) 121.0(3)
C(9)–C(10) 1.376(5) C(13)–C(12)–C(17) 117.9(3)
C(9)–Cl(1) 1.746(3) C(13)–C(12)–C(1) 121.7(3)
C(10)–C(11) 1.395(5) C(17)–C(12)–C(1) 120.4(3)
C(12)–C(13) 1.388(4) C(14)–C(13)–C(12) 122.0(3)
C(12)–C(17) 1.388(4) C(15)–C(14)–C(13) 117.9(3)
C(13)–C(14) 1.382(5) F(1)–C(15)–C(14) 119.3(3)
C(14)–C(15) 1.370(4) F(1)–C(15)–C(16) 118.7(3)
C(15)–F(1) 1.355(4) C(14)–C(15)–C(16) 122.0(3)
C(15)–C(16) 1.374(4) C(17)–C(16)–C(15) 119.2(3)
C(16)–C(17) 1.374(4) C(16)–C(17)–C(12) 120.9(3)
N(1)–N(2) 1.372(3) C(2)–N(1)–N(2) 108.1(2)
C(3)–N(2)–C(4) 108.1(2)
C(2)–C(1)–C(12) 114.9(3) C(3)–N(2)–N(1) 118.1(2)
N(1)–C(2)–C(1) 122.2(3) C(4)–N(2)–N(1) 133.8(2)
N(1)–C(2)–S(1) 116.9(2) C(3)–N(3)–C(6) 103.5(2)
C(1)–C(2)–S(1) 120.9(2) C(3)–S(1)–C(2) 87.81(14)
N(3)–C(3)–N(2) 112.3(3)
N(3)–C(3)–S(1) 138.7(2)
376 A. Banu et al.where the sixmolecules connects themselves into a perfect cyclo-
hexagonal ring pattern along ‘a’ axis (Fig. 4). The function of the
C–F group in crystal packing helps in the understanding of the
binding of a ﬂuorinated substrate to a macromolecular receptor
(Evans and Seddon, 1997; Glusker, 1995). The C–H  F inter-Figure 3 Packing of the molecules in crystal of (3a) viewed along ‘a
resulting in dimers and bifurcated bond.action (3.284 A˚) has the least donor–acceptor distance com-
pared to C–H  N (3.536 A˚), which makes the C–H  F bond
a successful competitor for the C–H donor. This is unusual since
it happens in the presence of oxygen and nitrogen which are
strong acceptor atoms, thus making the C–H  F interaction
an important structure-directing entity. The molecular packing
is further stabilized by p–p stacking interactions between the
benzene and imidazothiadiazole ring systemswithC2–C7 atoms
of the twomolecules being separated by a distance of 3.757(4) A˚
(symmetry code:½x, y,z) strengthening the supramolecular’ axis. Dotted lines indicate C–H  N intermolecular interactions
Figure 4 Packing of the molecules of (3a) with dotted lines indicating C–H  F intermolecular interactions generating hexagonal
hydrogen bond along ‘a’ axis.
Figure 5 View of the molecular packing in (3b), showing bifurcated C–H  N interactions along ‘b’ axis.
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compound (3a), the C–H  F interactions play important role
in the formation of the supramolecular network inﬂuencing
the conformation and property of imidazo-thiadiazole
derivatives.
The compound (3b) has a chloro group substituted at the
para position of the phenyl ring. The dihedral angle between
ﬂuorobenzyl and imidazo-thiadaizole is 79.54(3) indicating
that the two are oriented orthogonally. Chlorophenyl and imi-
dazothiadiazole are coplanar; the dihedral angle is 7.73(4)
between them. The C3‚N3 bond length of 1.330(4) A˚ con-
ﬁrms it as a double bond. The C2–N1 bond length of
1.289(4) A˚ and the N1–N2 bond length of 1.372(3) A˚ are rel-
atively short, suggesting some degree of delocalization in the
imidazothiadiazole system. The cis orientation of the ﬂuorob-
enzyl group and thiadiazole moiety is characterized by the tor-
sion angle C(12)–C(1)–C(2)–S(1) [41.5(3)] in the molecule.
The imidazole part of this imidazothiadiazole system is more
resonance stabilized due to the difference in bond lengthsS1–C3 [1.729(3) A˚] and S1–C2 [1.750(3) A˚]. Additionally, the
imidazothiadiazole entity is as usual planar and rigid. Most
of the imidazothiadiazole derivatives posses near or total
planarity locking the molecules conformationally into pseudo
ring moieties, and self-aggregates through weak C–H  N
interactions (Begum et al., 2006, 2007).
Despite the presence of elements like chlorine; sulphur
ﬂuorine etc, there are no interesting intermolecular interactions
in the crystal structure of compound (3b). However, the
molecular packing of this compound is rendered cohesive by
molecules linked via two C–H  N hydrogen bond interactions
(Begum et al., 2007).
The intra and intermolecular packing features seen in 3b are
very similar to the one observed in molecule 3a by the presence
of bifurcated and p–p stacking interactions (Fig. 5). The p–p
stacking interaction between the imidazothiadiazole and
benzene rings (Begum et al., 2007) being separated by a
distance of 3.785(2) A˚ (symmetry code:½+x, ½+y, ½z)
further strengthens the supramolecular structure. So the
378 A. Banu et al.supramolecular aggregation in this structure is limited to the
formation of these bifurcation and p–p stacking interactions.
5. Conclusion
The synthesis as well as the characterization of imidazo[2,
1-b][1,3,4]thiadiazole and its chlorophenyl derivative are
described with promising biological and pharmacological
activities. Additionally, the single crystal X-ray diffraction
analysis revealed certain interesting features such as the non-
planarity of the molecule due to the orthogonal orientation
of ﬂuorobenzyl with the imidazo-thiadiazole ring, presence of
a strong intramolecular hydrogen bond and the conforma-
tional rigidity of the pseudo ﬁve-membered ring. The stabiliza-
tion of the structure due to intermolecular C–H  F and
C–H  N interactions were analyzed wherein the supramolec-
ular aggregation in the molecule highlights a very interesting
molecular packing feature on C–H  F interaction where the
six molecules connect themselves into a perfect hexagonal
geometry depicting a cyclohexagonal ring pattern in order to
establish the construction of crystalline superstructures.
Supplementary material
Crystallographic data for the structures (3a) and (3b) reported
in this paper have been deposited with the Cambridge data
centre. The deposition numbers are CCDC 787336 and CCDC
763066.
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